Qualcomm, Inc. (QCOM) Estimates Lowered On Omnitracs Sale

0
Qualcomm, Inc. (QCOM) Estimates Lowered On Omnitracs Sale

Analysts Simona Jankowski, Doug Clark and Balaji Krishnamurthy at Goldman Sachs Group Inc (NYSE:GS) rate Qualcomm as a Buy.

Consistent with guidance, QUALCOMM, Inc. (NASDAQ:QCOM) completed the sale of Omnitracs, a subsidiary providing fleet management and logistics solutions, to Vista Equity Partners for $800M in cash. As previously guided, Qualcomm expects the divestiture will contribute $0.22-0.25 in EPS in 1QFY14 (Dec), which the company will include in both GAAP and non-GAAP EPS, which would imply an updated FY14 non-GAAP EPS guidance range of $5.17-5.40.

Exclusive: Third Point Expands Private Equity Business With New $300 Million Fund

Nestle Dan Loeb Daniel Loeb third point capital hedge fund manager activist investor poison pen activism Yahoo corporate governance famous investorsDan Loeb's Third Point recently completed the first close for TPVC, its new dedicated private growth-stage fund. The $300 million fund is part of Third Point's private investing strategy. At the end of February, Third Point managed $16.5 billion overall for clients around the world. New talent According to an investor update dated March 5th Read More


Also see: Qualcomm The Target Of Chinese Anti-Monopoly Probe

Qualcomm’s Omnitracs sales

QUALCOMM, Inc. (NASDAQ:QCOM)’s current FY14 revenue guidance $26.0-27.5 billion (5-11% growth) already assumed only a partial quarter of Omnitracs revenue. The company estimates the sale of Omnitracs equates to about a 1 percentage point drag on full year revenue growth. Firm’s prior estimates did not include the sale, so analysts are lowering their FY14 (Sep) revenue estimate to $27.0bn from $27.3bn (for reference, Omnitracs had $372 million in sales in FY13). Their FY14 EPS goes up to $5.51 from $5.28 to reflect the gain, which the company will include in non-GAAP EPS.

This will likely be only partially reflected in consensus, creating some confusion over the next quarter. Anaysts’ FY15/16 EPS estimates ticked down by $0.01 on the removal of Omnitracs. They see the sale as consistent with QUALCOMM, Inc. (NASDAQ:QCOM)’s increased focus on shareholder returns and cost controls. The $800 million boosts Qualcomm’s domestic cash balance to slightly under $9 billion. In addition, Qualcomm can more effectively focus on core R&D initiatives while reducing combined R&D and SG&A growth to 5-7% in FY14 vs. 23% growth in FY13.

Qualcomm’s valuation

There is no change to Goldman’s 12-month price target $82, based on 15X firm’s CY14 non-GAAP EPS of $5.44 (down from $5.45 due to Omnitracs).

Qualcomm’s key risks

Risks include lower device ASPs, royalty rate fluctuations, legal challenges, increasing competition, vertical integration, and customer concentration.

No posts to display